-transparent.png){kind=logo}
Diabetic patients often develop hypertension, and the presence of both hypertension and diabetes doubles the risk of death from coronary heart disease (CHD). Moreover, the presence and importance of abnormalities such as high low-density lipoprotein (LDL) cholesterol and triglycerides levels as CHD risk factors in insulin-dependent diabetes mellitus type 1 have been downplayed, while increasing evidence suggests that the management of type 1 patients should include control of dyslipidemia and hyperglycemia and an effective antihypertensive treatment able also to reduce risk factors for coronary artery events. In this study we assessed the antihypertensive and metabolic effects of doxazosin in hypertensive patients with type 1 diabetes. We show that the drug normalizes blood pressure, and while no improvement in glucose control was observed, it reduced total cholesterol and increased HDL cholesterol as well as the HDL to total cholesterol ratio. The changes of the various parameters studied, including the calculated CHD risk score based on the Framingham equation, suggest that doxazosine can reduce the CHD risk for hypertensive type 1 patients.
L Calò, and
P A Davis, and
S Cantaro, and
L Bonfante, and
R Castrignano, and
G Carraro, and
A D'Angelo
December 1988,
American heart journal,
L Calò, and
P A Davis, and
S Cantaro, and
L Bonfante, and
R Castrignano, and
G Carraro, and
A D'Angelo
January 1996,
The Journal of international medical research,
L Calò, and
P A Davis, and
S Cantaro, and
L Bonfante, and
R Castrignano, and
G Carraro, and
A D'Angelo
January 1998,
Terapevticheskii arkhiv,
L Calò, and
P A Davis, and
S Cantaro, and
L Bonfante, and
R Castrignano, and
G Carraro, and
A D'Angelo
January 1992,
European journal of clinical pharmacology,
L Calò, and
P A Davis, and
S Cantaro, and
L Bonfante, and
R Castrignano, and
G Carraro, and
A D'Angelo
January 1986,
Postgraduate medical journal,
L Calò, and
P A Davis, and
S Cantaro, and
L Bonfante, and
R Castrignano, and
G Carraro, and
A D'Angelo
January 1998,
Clinical drug investigation,
L Calò, and
P A Davis, and
S Cantaro, and
L Bonfante, and
R Castrignano, and
G Carraro, and
A D'Angelo
July 1993,
La Clinica terapeutica,
L Calò, and
P A Davis, and
S Cantaro, and
L Bonfante, and
R Castrignano, and
G Carraro, and
A D'Angelo
September 2003,
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
L Calò, and
P A Davis, and
S Cantaro, and
L Bonfante, and
R Castrignano, and
G Carraro, and
A D'Angelo
June 1996,
Kidney international. Supplement,
L Calò, and
P A Davis, and
S Cantaro, and
L Bonfante, and
R Castrignano, and
G Carraro, and
A D'Angelo
July 1966,
Diabetes,
